+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical Study of Sequential Therapy with Abiraterone and Enzalutamide Following Docetaxel Therapy for Castration-Resistant Prostate Cancer



Clinical Study of Sequential Therapy with Abiraterone and Enzalutamide Following Docetaxel Therapy for Castration-Resistant Prostate Cancer



Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 108(2): 74-79



(Purpose) This study is to evaluate the efficacy and safety of sequential therapy with two novel drugs, abiraterone and enzalutamide after docetaxel (DOC) therapy for castration-resistant prostate cancer (CRPC). (Material and methods) Twenty-one patients were identified received sequential therapy with abiraterone and enzalutamide after DOC therapy at our institution. We investigated PSA response (decrease of 50% or more) to prior administered drug as primary endpoint, and overall survival rate and occurrence of adverse events as secondary endpoint. (Results) There were 12 patients in the group preliminarily administered enzalutamide (Group E) and 9 patients in the group preliminarily administered abiraterone (Group A). The novel drugs were administered immediately following DOC therapy in nearly all cases. Of the 9 patients in Group A, only one patient (11%) and of the 12 patients in Group E, only one patient (9%) achieved PSA decrease of 50% or more, thus resulting in a poor response rate. There was not significantly difference in both groups. The overall survival rates of Group A and E were not significantly difference. There were three adverse events which required change drug. Those were two cases (appetite loss and general fatigue) on enzalutamide and one case (edema) on abiraterone. (Conclusion) This study suggested that sequential therapy with abiraterone and enzalutamide after DOC therapy had poor clinical benefit regardless of the order of administration of both drugs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054968816

Download citation: RISBibTeXText

PMID: 29669980

DOI: 10.5980/jpnjurol.108.74


Related references

Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer. Advances in Therapy 31(2): 234-241, 2014

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clinical Genitourinary Cancer 16(2): 130-134, 2018

Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. Prostate 77(10): 1144-1150, 2017

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 74(13): 1278-1285, 2014

Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Prostate 78(4): 250-256, 2018

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 120(7): 968-975, 2014

Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]. Der Urologe. Ausg. a 53(11): 1665-1667, 2014

Study on the therapy of castration-resistant prostate cancer : Randomized phase II study of abiraterone acetate with LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naive castration-resistant prostate cancer (SPARE) - AP 67/11 of the Association of Urogenital Oncology (AUO). Der Urologe. Ausg. a 55(5): 665-667, 2016

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. European Urology 65(1): 30-36, 2014

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 13(4): 392-399, 2015

Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer 16(2): 142-148, 2018

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. Bmc Cancer 17(1): 677, 2017

Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan. Clinical Genitourinary Cancer 15(2): 313-319, 2017

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget 9(28): 19861-19873, 2018

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of Oncology 24(7): 1807-1812, 2013